文献速递心力衰竭与心肌病

私募股权收购美国医院后心力衰竭患者的诊疗与结局

Heart Failure Care and Outcomes After Private Equity Acquisition of U.S. Hospitals.
PubMed 文献 · J Am Coll Cardiol · 2025-06-09

本研究识别2012至2019年被私募股权收购的美国医院及匹配对照医院,采用准实验双重差分法分析65岁及以上心力衰竭Medicare按服务付费受益人的临床结局、收治与转院病例组合及心脏手术使用变化。结果显示收购后30天死亡率与30天再就诊率无显著变化,但黑人患者转出率显著增加,心导管检查率显著上升。

要点

  • 私募股权收购医院后心衰患者30天死亡率与再就诊率无显著变化
  • 收购后黑人心衰患者转出至其他机构的比例显著增加
  • 收购后心衰患者心导管检查率显著上升

核心结论

  • 私募股权收购美国医院未改善老年心力衰竭患者的结局,尽管收治患者的临床风险有所下降。

研究设计与样本

  • 准实验双重差分分析,纳入2012至2019年被私募股权收购的41家美国医院与192家匹配对照医院。
  • 研究对象为65岁及以上心力衰竭的Medicare按服务付费受益人。

主要发现

  • 收购后30天死亡率无变化(DiD +0.7个百分点,95%CI:-0.4至1.8)。
  • 收购后30天再就诊率无变化(DiD -0.2个百分点,95%CI:-0.9至0.5)。
  • 与匹配对照医院相比,收购医院收治心衰患者的临床风险显著下降。
  • 总体转院率无变化,但黑人患者转出至其他机构显著增加(DiD +7.1个百分点,95%CI:0.7至13.4),其他种族未观察到该变化。
  • 收购医院心衰患者心导管检查率显著上升(DiD +0.7个百分点,95%CI:0.1至1.2)。

临床怎么用

  • 关注私募股权收购医院后心衰患者的转院模式,尤其是黑人患者转出率增加的现象。
  • 关注收购后心导管检查率上升是否与临床需要相匹配。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Private equity firms have rapidly acquired U.S. hospitals and increasingly invested in cardiology over the past decade. However, little is known about how private equity acquisition of hospitals affects care and outcomes for patients with heart failure. OBJECTIVES: The purpose of this study was to evaluate whether clinical care and outcomes changed for patients with heart failure after the acquisition of U.S. hospitals by private equity firms compared with matched control hospitals. METHODS: This study identified U.S. hospitals acquired by private equity firms and matched control hospitals from 2012 through 2019. A quasiexperimental difference-in-differences analysis was used to evaluate changes in clinical outcomes, the case mix of admissions and transfers, as well as cardiac procedure utilization among Medicare fee-for-service beneficiaries aged 65 years or older with heart failure. RESULTS: There were 41 private equity-acquired hospitals and 192 matched control hospitals. After private equity acquisition of hospitals, there was no change in 30-day mortality rates (difference-in-differences [DiD] +0.7 percentage points [95% CI: -0.4 to 1.8]) or 30-day hospital revisit rates (DiD -0.2 percentage points [95% CI: -0.9 to 0.5]), despite a significant decrease in the clinical risk of patients with heart failure when compared with those at matched control (nonacquired) hospitals. Overall hospital transfer rates did not change, but Black patients were significantly more likely to be transferred out to another site after private equity acquisition (DiD +7.1 percentage points [95% CI: 0.7-13.4]), a change not observed across other racial groups. In addition, there was a significant increase in cardiac catheterization rates (DiD estimate, +0.7 percentage points [95% CI: 0.1-1.2]) among heart failure patients at private equity-acquired vs control hospitals. CONCLUSIONS: These findings suggest that private equity acquisitions of U.S. hospitals do not improve outcomes among older adults with heart failure, despite a decrease in the clinical risk of patients admitted to these sites.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Johnson, Liu, Bartlett, et al. Heart Failure Care and Outcomes After Private Equity Acquisition of U.S. Hospitals. J Am Coll Cardiol. 2025. PMID: 40492998. doi:10.1016/j.jacc.2025.05.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。